结直肠癌患者阿司匹林及其他非甾体抗炎药使用时机与肿瘤标志物及生存的关系
基于美国、加拿大和澳大利亚人群癌症登记中1997至2008年诊断的2419例18至74岁浸润性结直肠癌患者,分析诊断后阿司匹林及其他非甾体抗炎药使用时机与肿瘤标志物及生存的关系。中位随访10.8年,诊断后单用阿司匹林者总生存(HR 0.75,95%CI 0.59-0.95)和结直肠癌特异性生存(HR 0.44,95%CI 0.25-0.71)更优;诊断后任何非甾体抗炎药使用与总生存的关联因KRAS突变状态而异(交互作用P=0.01),仅在KRAS野生型肿瘤中与总生存改善相关(HR 0.60,95%CI 0.46-0.80)。
要点
- 诊断后单用阿司匹林与更优总生存(HR 0.75)和结直肠癌特异性生存(HR 0.44)相关。
- 诊断后任何非甾体抗炎药使用与总生存的关联因KRAS突变状态显著不同(交互作用P=0.01)。
- 仅在KRAS野生型肿瘤中,诊断后任何非甾体抗炎药使用与总生存改善相关(HR 0.60)。
核心结论
- 在长期结直肠癌生存者中,诊断后规律使用非甾体抗炎药与KRAS野生型肿瘤个体生存改善显著相关。
研究设计与样本
- 研究纳入美国、加拿大和澳大利亚人群癌症登记中1997至2008年诊断的2419例18至74岁浸润性结直肠癌患者。
- 研究在入组和5年随访时发放详细流行病学问卷,并通过链接国家死亡登记完成生存结局。
- 研究评估BRAF和KRAS突变状态、微卫星不稳定性和CpG岛甲基化表型,采用Cox比例风险回归估计总生存和结直肠癌特异性生存的风险比(HR)及95%CI。
主要发现
- 自诊断起中位随访10.8年,观察到381例死亡,其中100例归因于结直肠癌。
- 与非使用者相比,诊断后单用阿司匹林者总生存更优(HR 0.75,95%CI 0.59-0.95),结直肠癌特异性生存更优(HR 0.44,95%CI 0.25-0.71)。
- 在开始使用阿司匹林者中,总生存(HR 0.64,95%CI 0.47-0.86)和结直肠癌特异性生存(HR 0.40,95%CI 0.20-0.80)更优。
- 诊断后任何非甾体抗炎药使用与总生存的关联因KRAS突变状态显著不同(交互作用P=0.01)。
- 诊断后任何非甾体抗炎药使用仅在KRAS野生型肿瘤参与者中与总生存改善相关(HR 0.60,95%CI 0.46-0.80),在KRAS突变型肿瘤参与者中未达统计学显著(HR 1.24,95%CI 0.78-1.96)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Regular use of aspirin is associated with improved survival for patients with colorectal cancer (CRC). However, the timing of and the subtype of CRC that would benefit the most from using aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) in relation to survival is unclear. Patients and Methods In all, 2,419 patients age 18 to 74 years with incident invasive CRC who were diagnosed from 1997 to 2008 were identified from population-based cancer registries in the United States, Canada, and Australia. Detailed epidemiologic questionnaires were administered at study enrollment and at 5-year follow-up. Survival outcomes were completed through linkage to national death registries. BRAF- and KRAS-mutation status, microsatellite instability, and CpG island methylator phenotype were also evaluated. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% CIs for overall survival (OS) and CRC-specific survival. Results After a median of 10.8 years of follow-up since diagnosis, 381 deaths (100 as a result of CRC) were observed. Compared with nonusers, postdiagnostic aspirin-only users had more favorable OS (HR, 0.75; 95% CI, 0.59 to 0.95) and CRC-specific survival (HR, 0.44; 95% CI, 0.25 to 0.71), especially among those who initiated aspirin use (OS: HR, 0.64; 95% CI, 0.47 to 0.86; CRC-specific survival: HR, 0.40; 95% CI, 0.20 to 0.80). The association between any NSAID use after diagnosis and OS differed significantly by KRAS-mutation status ( Pinteraction = .01). Use of any NSAID after diagnosis was associated with improved OS only among participants with KRAS wild-type tumors (HR, 0.60; 95% CI, 0.46 to 0.80) but not among those with KRAS-mutant tumors (HR, 1.24; 95% CI, 0.78 to 1.96). Conclusion Among long-term CRC survivors, regular use of NSAIDs after CRC diagnosis was significantly associated with improved survival in individuals with KRAS wild-type tumors.
引用
- Hua X, Phipps AI, Burnett-Hartman AN, et al. Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival. J Clin Oncol. 2017. PMID: 28617623. doi:10.1200/JCO.2017.72.3569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。